The increased armament in the battle against non-small-cell lung cancer
For decades, the prognosis for patients with non-resectable non-small-cell lung cancer (NSCLC) have remained grim with median survival times about six months for patients with locally advanced or metastatic disease taken together. These figures have nourished some therapeutic nihilism among many health care professionals who manage patients with this disease. However, over the past 5-10 years the use of systemic chemotherapy for NSCLC has gained an air of increasing optimism, which is based on several reasons. First of all, meta-analyses of randomised trials involving cisplatin-based combination regimens compared with best supportive care have recently been published [1, 2] . The meta-analyses have clearly documented a modest benefit of two to three months in median survival and a doubling of the one-year survival rate. The survival improvement is statistically significant and indicates that the course of the disease can be influenced by systemic treatment.
Secondly, while it is clear that the current status of chemotherapy in locally advanced or metastatic disease have its limitations, the issue of quality of life has been focused upon, which is of importance also due to the toxicity of the cytostatic agents. There is evidence that combination chemotherapy may reduce specific symptoms such as pain, cough and dyspnoea [3, 4] . Indeed, improvement in disease related symptoms may be observed in more than half of the patients treated, including many patients who do not clearly demonstrate a decrease in tumour size by objective response assessment.
A third factor which holds promises for the future in the treatment of NSCLC is the recent development and subsequent use in clinical trials of a range of new cytostatic agents, including the antimetabolite gemcitabine, the topoisomerase 1 inhibitor CPT-11, the vinka alkaloid vinorelbine, and the taxanes paclitaxel and docetaxel. All of these new agents consistently yield response rates > 20% when used as single agents [5] . Further clinical trials have to establish the best use of these active new agents in the treatment of NSCLC, and a study by Manegold et al. [6] in this issue of Annals of Oncology represents one approach to this. Single agent gemcitabine was compared to a combination of etoposide and cisplatin in a two-armed randomised phase II study including 138 evaluable patients with locally advanced or metastatic NSCLC. No difference in activity was encountered, as partial responses were seen in 12 patients receiving gemcitabine (18%; 95% confidence limits 9.8-30) and in 11 patients receiving etoposide and cisplatin (15%; 95% confidence limits 7.9-25.7). Similarly, there were no significant differences with respect to time to disease progression (median 4.2 months and 4.9 months, respectively) or survival (median 6.6 months and 7.6 months, respectively). In contrast, differences in alopecia, nausea and vomiting and also in hospitalization because of neutropenic fever in favour of gemcitabine treatment were observed, while data on symptom status and quality of life are not provided. This study thus confirms the single agent activity for gemcitabine with respect to response rate. However, the study also opens for additional questions, one of which may be the crucial question whether the patients receiving single agent gemcitabine actually had benefit in terms of improved quality of life. Even though the toxicity with gemcitabine at some points are lower than that of etoposide and cisplatin, clearly there are toxicities encountered with the single agent treatment. This must be balanced against a possible, but as yet not documented, benefit in terms of quality of life or at least in improving specific symptoms in order for gemcitabine to be used as a single agent in the armamentarium for the treatment for NSCLC. Such analyses are indeed both important and necessary and are awaited with interest.
Another question put forward by the study by Manegold et al. [6] is how we make the best use and interpretation of randomised phase II trials. The concept of randomised phase II clinical trials was described already in 1985 by Simon et al. [7] with the major objective to fascilitate the interpretation of the response rate observed with an investigative treatment. Clearly, one of the advantages for randomised phase II trials may be to offer a rapid method for evaluation of different new treatment regimens. On the other hand, when a standard treatment is included among the regimens to be randomised between, difficulties in the interpretation of the results may occur because of lack of statistical power in the comparison. One way to deal with this problem is the conduction of a properly dimensioned classical randomised phase III trial, e.g., such as recently published in an evaluation of vinorelbine, one of the other promising new agents, in a three-armed study including more than 600 patients with one of the treatment options being vinorelbine as a single agent [8] .
Further evaluation of new cytostatic agents possessing activity in NSCLC includes evaluation in combination chemotherapy regimens, and such studies using combinations with either cisplatin or carboplatin, as well as other agents, are in progress. Some of these investigative regimens have revealed response rate of 50% or more in phase II studies among patients with locally advanced or metastatic disease, and obviously needs con-firmation in randomised settings. However, if such results can be confirmed in large scale trials it holds promise for an improvement in the survival and palliation of symptoms in larger proportions of the patients with non-resectable NSCLC treated than is the case today. Future studies employing such new active regimens among patients with a smaller tumour burden, such as in an adjuvant and neo-adjuvant setting, is of equal importance. When used in this way among patients with a minimal tumour burden, chemotherapy may possibly in the future turn out to have a curative potential also in NSCLC when used together with other treatment modalities like surgery or radiotherapy or both, e.g., as previously documented in other malignant diseases such as adjuvant chemotherapy in breast cancer and more recently also in colorectal cancer.
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